Search Results
Apr 07, 2026, 08:55 ET Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Apr 07, 2026, 06:30 ET Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with 2 or more ALK tyrosine kinase inhibitors and orphan drug designation for ALK-positive NSCLC.About
More news about: Nuvalent, Inc.
Apr 06, 2026, 23:28 ET Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
April 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label, single-arm, multicenter
More news about: Akeso, Inc.
Apr 06, 2026, 15:28 ET ArtemiLife Nears Milestone in Landmark Prostate Cancer Clinical Trial
Breast Cancer — Exploring ArtemiCafé®'s potential role in maintenance therapy for breast cancer patients following standard treatment.Lung Cancer — Investigating whether Artemisia annua compounds may support outcomes in one of the most prevalent and deadly cancers globally.Preventive
More news about: ArtemiLife
Apr 06, 2026, 15:23 ET Brayton Purcell LLP Highlights East Coast Symposium Addressing Escalating Artificial Stone Silicosis Crisis
Calif., April 6, 2026 /PRNewswire/ -- As national attention intensifies around a rapidly escalating occupational lung disease affecting countertop fabrication workers, Brayton Purcell LLP is participating in a major East Coast symposium examining the growing
More news about: Brayton Purcell LLP
Apr 06, 2026, 14:56 ET TGH Cancer Institute and USF Health Morsani College of Medicine Convene International Scientific Leaders for the "Microbes, Genes & Cancer" Symposium
Hopkins University and a leader in cancer immunotherapy and immune checkpoint research; Dr. Warren Leonard, senior investigator at the National Heart, Lung, and Blood Institute at the National Institutes of Health and a leading authority in cytokine and T cell biology; and Dr. Rafi Ahmed, director of the
More news about: Tampa General Hospital
Apr 06, 2026, 11:00 ET DELFI Diagnostics to Showcase Whole-Genome cfDNA Platform Advances in Cancer Detection and Monitoring at AACR 2026 Annual Meeting
blood, an approach known as fragmentomics, to help detect lung cancer with high sensitivity. FirstLook Lung, the first commercially available blood-based screening test for lung cancer in the United States, serves individuals eligible for lung cancer screening through a simple blood draw that integrates
More news about: DELFI Diagnostics
Apr 06, 2026, 09:10 ET Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Apr 06, 2026, 09:08 ET Pan Am Cancer Expands Global Leadership in Personalized Cancer Immunotherapy by Collaboration with Internationally Renowned Cancer Pioneer Dr. Baofa Yu
often producing abscopal effects against distant metastases with no side effects and potent responses in hundreds of patients with advanced cancers like lung, liver, and pancreatic tumors."Dr. Baofo is internationally recognized as the pioneer in non-toxic, immune based therapies. After his mother passed
More news about: Pan Am Cancer Treatment Centers
Apr 06, 2026, 09:00 ET Abbott recebe aprovação regulatória no Brasil de serplulimabe, novo medicamento biológico para o tratamento de câncer de pulmão de pequenas células com doença extensa, oferecendo uma nova alternativa para pacientes
Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients. Clin Lung Cancer. 2024;25(2): e101-e111.e2. doi: 10.1016/j.cllc.2023.11.009Instituto Oncoguia. Câncer de pulmão chega em fase avançada
More news about: Abbott
Apr 06, 2026, 07:30 ET Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3
More news about: Actinium Pharmaceuticals, Inc.
Apr 06, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
pharmacokinetics of IDE574 as a monotherapy in the Phase 1 dose escalation trial in solid tumor patients, including breast, prostate, colorectal, and lung cancer.
More news about: IDEAYA Biosciences, Inc.
Apr 04, 2026, 12:06 ET Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Independent Data Monitoring Committee (IDMC) for the TACTI 004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: THE ROSEN LAW FIRM, P. A.
Apr 03, 2026, 11:35 ET Pulmonary Fibrosis Foundation Announces 2026 PFF Walk Season
remind all of us that no one is alone."More than 250,000 Americans are living with pulmonary fibrosis and interstitial lung disease, serious and life-threatening lung conditions that can cause permanent scarring in the lungs and make it increasingly difficult to breathe. Funds raised through
More news about: The Pulmonary Fibrosis Foundation
Apr 03, 2026, 10:30 ET Next Generation Drug Conjugates (NDCs) Market worth $42.55 billion by 2035 | MarketsandMarkets™
approvals across multiple HER2-targeted indications, particularly in breast cancer. Its growing use in HER2-low populations and ongoing clinical trials in lung and gastric cancers further support its market leadership. Additionally, the increasing prevalence of breast cancer and the rising demand for targeted
More news about: MarketsandMarkets
Apr 03, 2026, 08:00 ET New Physician from Leading Sarasota Cardiology Practice to Now Offer the Hybrid Choice™ Concierge Program from Concierge Choice Physicians
internal medicine residency at Morristown Medical Center in Morristown, NJ. He then completed a cardiovascular fellowship at the esteemed Deborah Heart and Lung Center in Browns Mills, NJ.Dr. Buck holds board certifications in general cardiology, echocardiography, nuclear cardiology, and Cardiovascular
More news about: Concierge Choice Physicians
Apr 02, 2026, 23:11 ET Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis
generic therapeutic equivalent of Ofev®, marketed by Boehringer Ingelheim. IPF is a chronic, progressive lung disease characterized by irreversible scarring of lung tissue, leading to declining lung function and significant impact on patients' quality of life.Commenting on the approval Marc Falkin,
More news about: Cipla USA Inc.
Apr 02, 2026, 20:37 ET GOSS Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Gossamer Bio, Inc.
company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.
More news about: Robbins LLP
Apr 02, 2026, 11:51 ET Nhà tắm Flamingo Estate do Kohler thiết kế ra mắt như một thánh địa nghỉ dưỡng và chăm sóc sức khỏe hòa quyện với thiên nhiên tại Tuần lễ Thiết kế Milan 2026
nắng mặt trời xuyên qua những ô cửa sổ kính màu cỡ lớn, trong khi 200 ngọn nến Flamingo Estate tô điểm cho các bức tường của nhà tắm, làm tăng thêm vẻ lung linh và tạo một không gian cho chiều sâu của sự thanh bình và thư thái.Thiết kế phủ đồng trưng bày tại Milan đúc kết 153 năm kinh nghiệm chế
More news about: Kohler Co.
Apr 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
Apr 02, 2026, 09:50 ET Florida Cancer Specialists & Research Institute Contributes to Phase 1 Study Demonstrating Antitumor Activity with First-in-Class KRAS-Targeted Therapy for Treatment of Lung and Pancreatic Cancers
Research Institute, LLC (FCS) have provided significant insights into the safety and efficacy of setidegrasib in patients with advanced non-small-cell lung cancer and pancreatic cancer with KRAS G12D mutations. Setidegrasib is a first-in-class therapy that targets and breaks down KRAS G12D, a genetic mutation
More news about: Florida Cancer Specialists & Research Institute
Apr 02, 2026, 08:00 ET Accent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting
Findings reinforce the multi-tumor potential of KIF18A inhibitor, ATX-295, in high-grade serous ovarian, squamous non-small cell lung, and triple-negative breast cancer modelsLEXINGTON, Mass., April 2, 2026
More news about: Accent Therapeutics
Apr 01, 2026, 23:59 ET 再鼎醫藥宣佈達成全球臨床研究合作及供應協議，以評估創新性DLL3抗體藥物偶聯物Zocilurtatug Pelitecan與雙特異性T細胞銜接器的聯合治療
References:[1] J Thorac Oncol. 2023 Jan;18(1):31-46; Lung Cancer Foundation of America. [2]
More news about: 再鼎醫藥
Apr 01, 2026, 12:37 ET NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
Mammography Workflows to Promote Lung Cancer Screening: A Feasibility Study," "A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs)," and "Increasing Equitable Adherence to Annual Lung Cancer Screening and Diagnostic
More news about: National Comprehensive Cancer Network
Apr 01, 2026, 09:00 ET IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Trial Futility: Levi & Korsinsky
that an Independent Data Monitoring Committee (IDMC) recommended halting the Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small-cell lung cancer because an interim futility analysis showed the drug was unlikely to meet its efficacy endpoints. If you suffered a loss on your Immutep investment,
More news about: Levi & Korsinsky, LLP